CompoAtlas

Saffron

Saffron, licence 80097012: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Natural health product licensed in Canada

Other names
Ado Zen, Saffron Zen, Safran Zen, Teen Zen
Licence holder
New Roots Herbal Inc.
NPN or DIN-HM
80097012
Status
Active licence
Licence date
6 February 2020
Revision date
3 October 2024
Form
Capsule
Route of administration
Orale
Application type
Générale (non traditionelle)

If this product were sold in France

No point flagged by the rules we apply.

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal composition not provided.

Non-medicinal ingredients

Cellulose microcristalline, NA, Stéarate de magnésium, Eau purifiée, Dioxyde de silicium

PopulationAgeQuantity per servingFrequency
Adolescentesminimum: 12.0 Année(s) ; maximum: 17.0 Année(s)1.0 Capsule2.0 Jour(s)
Adultesminimum: 18.0 ans1.0 Capsule2.0 Jour(s)

Uses authorised in Canada

Helps to support mood balance. Helps to support mood balance in adolescents and youths 12 years and over. Affron Helps to relieve restlessness and/or nervousness (calmative). Supports positive effects on symptoms of perceived stress such as, fatigue, weariness, and irritability. Helps to reduce the symptoms of perceived stress, such as fatigue, weariness, and irritability. Helps to improve restorative sleep, in individuals experiencing sleeplessness. Helps improve sleep quality in individuals experiencing sleeplessness. Helps to support/maintain (healthy) mood balance. Clinically proven to support/maintain (healthy) mood balance. Affron is clinically shown to relieve restlessness and/or nervousness (calmative). Clinically shown to support positive effects on symptoms of perceived stress such as, fatigue, weariness, and irritability. Clinically shown to reduce the symptoms of perceived stress, such as fatigue, weariness, and irritability. Clinically shown to improve restorative sleep, in individuals experiencing sleeplessness. Supports the management of symptoms associated with perimenopause. Helps improve sleep quality. Clinically proven to help improve sleep quality. Clinically proven to help improve sleep quality in 4 weeks. Clinically proven to improve sleep quality in individuals experiencing sleeplessness. May help to support healthy mood balance during perimenopause. Helps to support healthy mood balance during perimenopause. Clinically shown to help relieve symptoms associated with perimenopause. Helps to support mood balance after awakening. Helps to support healthy mood balance after awakening.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

Source

Official Health Canada record, licence 80097012

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).

List recorded in 2024. Photograph the packaging to check whether it has changed.

Has the product changed? Photograph the packaging.

List recorded in 2024. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line